Group 1 - The core viewpoint of the report is that Citi has lowered the earnings forecast for Tigermed (300347) for the fiscal year 2027 by 7% due to increased uncertainty regarding long-term investment returns [1] - Citi maintains a "Outperform" rating for Tigermed, reducing the target price for H-shares from HKD 68.2 to HKD 59.9, and for A-shares from RMB 81.9 to RMB 72 [1] - Although the order situation for Tigermed has improved, the market is more focused on the company's order conversion revenue efficiency and investment realization capability [1] Group 2 - Short-term positive factors have already been reflected in the stock price, leading to a belief that the risk and return have reached a balance [1]

Group 1 - The company has confirmed its investment in Angrui Micro, which is one of the projects under its subsidiary, Yuexiu Industrial Fund Management [2] - The investment's potential returns are uncertain, and stakeholders are advised to refer to the company's regular financial reports for detailed information [2]